Navigation Links
Fate Therapeutics Closes $30 Million Series B Financing
Date:11/16/2009

LA JOLLA, Calif., Nov. 16 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor. The three co-leaders of the Company's Series A financing, ARCH Venture Partners, Polaris Venture Partners and Venrock, also participated in the latest round of financing. In conjunction with the funding, Carl Weissman, managing director at OVP Venture Partners, joined the Company's board of directors.

"Fate Therapeutics has made rapid progress in advancing its pipeline of Stem Cell Modulators and in establishing the leading industrialized platform for induced pluripotent stem cell technology," said Mr. Weissman. "We are confident that the Company's management team and its scientists will continue to identify novel mechanisms to selectively intervene in adult stem cell biology for medicine, and we believe its expert knowledge, innovative approach and advanced technologies in modulating cell fate can be leveraged across a broad therapeutic spectrum of drug discovery and development opportunities."

"The leadership of OVP, the continued support of our top-tier existing investors, and the breadth of drug development and commercialization expertise of our corporate investor syndicate creates a powerful foundation for the expansion of our stem cell biology discovery engine," said Paul Grayson, president and CEO of Fate Therapeutics. "Target populations of adult stem cells must be exquisitely characterized and quantitated, and we are employing genomic, proteomic and epigenetic expression technologies to identify cell-specific biological mechanisms to modulate cell fate for diseases that currently have limited to no tre
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
2. Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
3. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
4. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
5. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
6. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
7. Tolera Therapeutics Files IND Application for TOL101, Appoints OToole to Lead Clinical Operations
8. Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
9. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
10. Oxygen Biotherapeutics, Inc. Expands Board of Directors
11. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), ... commercializing innovative therapies addressing major unmet medical needs ... the Notice of Allowance from the United States ... RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... LAUSANNE, Switzerland, September 3 Debiopharm Group, ... with,a focus on the development of prescription drugs ... Life Sciences Award, to Dr Lluis,Quintana-Murci from the ... in the emerging field of evolutionary genetics of,infection. ...
... JERUSALEM, September 3 Oramed Pharmaceuticals,Inc. (OTC ... systems, announced today that Nadav Kidron, its Chief Executive,Officer, is ... Conference on Friday September 11, 2009 at 10:00 a.m. EDT. ... in New York City. , Nadav ...
... , , BEIJING, Sept. 3 ... President Chung Leik Kok, announced today the signing of two (2) ... and Chemical Co., Ltd. (Beijing Oil & Gas). Fauve Intertrade is ... Miami, Florida; and Kuala Lumpur, Malaysia - with offices opening in ...
Cached Biology Technology:The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection 2The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection 3Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference 2Fauve Intertrade Signs Major Energy Contracts in China 2
(Date:4/23/2014)... a newly coined term for novels and films which focus ... of Copenhagen shows how these fictions serve as a mental ... climate change and imagine other living conditions. , "Global ... the atmosphere; it is also a cultural phenomenon in which ... the films we see. And there are so many of ...
(Date:4/23/2014)... University of Exeter researcher has shed light on how ... in Australia,s remote outback have become reviled as pests ... of the Environment and Sustainability Institute at the University ... camel in Australia, from their historic role helping to ... as unwelcome "invader." , The deserts of the Australian ...
(Date:4/23/2014)... leading a 2 million Food Standards Agency (FSA) project ... and industry workers. , Norovirus outbreaks can rapidly ... batch of frozen strawberries infected 11,000 people in Germany, ... of which strains cause infection and which foods are ... , Researchers will produce data that will help the ...
Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3
... States, (U.S.) predominance in science and technology (S&T) eroded ... China and South Korea--rapidly increased their innovation capacities. According ... Board (NSB), the policy making body of the National ... and Congress, the major Asian economies, taken together, now ...
... , This news release is available in ... transmission at the synapse between neurons is a highly complex, but ... voltage change, the so-called action potential, reaches the synaptic terminal in ... presynaptic neuron. This influx leads to a rise in the intracellular ...
... led by scientists from the University of California, San ... a protein that broadly regulates how genetic information transcribed ... ultimately translated into the myriad of proteins necessary for ... Cell Reports , help explain how a relatively ...
Cached Biology News:US lead in science and technology shrinking 2US lead in science and technology shrinking 3US lead in science and technology shrinking 4Loose coupling between calcium channels and sensors 2Global regulator of mRNA editing found 2
Human DPPII/QPP/DPP7 Biotinylated Affinity Purified PAb ENTREZ GeneID: 29952...
Human SorCS1 Affinity Purified Polyclonal Ab Protein Family: Neurotrophins...
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
hypertension-related calcium-regulated gene, mRNA...
Biology Products: